2982696-04-6
Chemical Structure
DN203316
Synonym(s): PPARδ agonist 11
- CAS No.: 2982696-04-6
- Formula:C19H15F3N2O3S2
- Molecular Weight:440.46
InChIKey: NLJZRFBMZSIDNW-UHFFFAOYSA-N
SMILES: CC1=CC(SCC(S2)=NN=C2C3=CC=C(C(F)(F)F)C=C3)=CC=C1OCC(O)=O
Biological Activity: DN203316 (PPARδ agonist 11) is a potent, selective, orally active PPARδ agonist (EC50 = 20 nM) with high selectivity over PPARα and PPARγ. DN203316 suppresses NF-κB-mediated inflammatory signaling, inhibits ferroptosis by upregulating xCT and GPX4, and attenuates STING-TBK1-IRF3-driven fibrogenic responses. DN203316 is useful for research on inflammatory disorders, metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DN203316 | DN203316 (PPARδ agonist 11) is a potent, selective, orally active PPARδ agonist (EC50 = 20 nM) with high selectivity over PPARα and PPARγ. DN203316 suppresses NF-κB-mediated inflammatory signaling, inhibits ferroptosis by upregulating xCT and GPX4, and attenuates STING-TBK1-IRF3-driven fibrogenic responses. DN203316 is useful for research on inflammatory disorders, metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kim J, et al., Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders. Eur J Med Chem. 2024 Sep 12;279:116856. [Content Brief]
- [2]. Kim YJ, et al. DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis. Exp Mol Med. 2026 Jun 5. [Content Brief]
Keywords
